Evergreen Private Wealth LLC Boosts Holdings in Zoetis Inc. $ZTS

Evergreen Private Wealth LLC raised its holdings in Zoetis Inc. (NYSE:ZTS) by 40.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 46,818 shares of the company’s stock after acquiring an additional 13,368 shares during the period. Zoetis makes up approximately 2.3% of Evergreen Private Wealth LLC’s portfolio, making the stock its 19th biggest position. Evergreen Private Wealth LLC’s holdings in Zoetis were worth $5,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Summit Place Financial Advisors LLC grew its holdings in Zoetis by 0.4% in the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock valued at $2,834,000 after buying an additional 76 shares during the period. CWA Asset Management Group LLC grew its holdings in Zoetis by 1.1% in the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock valued at $1,059,000 after buying an additional 80 shares during the period. YANKCOM Partnership grew its holdings in Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after buying an additional 81 shares during the period. Evergreen Capital Management LLC grew its holdings in Zoetis by 3.3% in the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock valued at $394,000 after buying an additional 85 shares during the period. Finally, Beese Fulmer Investment Management Inc. lifted its stake in shares of Zoetis by 2.4% in the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after purchasing an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Bank of America lifted their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. UBS Group set a $136.00 price objective on Zoetis in a research note on Thursday, January 29th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Citigroup started coverage on Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus target price of $152.25.

Zoetis Stock Performance

Zoetis stock opened at $117.46 on Thursday. The stock’s 50 day moving average price is $121.21 and its 200 day moving average price is $125.80. The firm has a market capitalization of $49.41 billion, a PE ratio of 19.51, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a one year low of $113.29 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s payout ratio is 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.